Stockscreener 앱 받기
2.40
0.00%
0.00
시간 외 거래:
2.40
전일 마감가:
$2.40
열려 있는:
$2.37
하루 거래량:
792.81K
Relative Volume:
0.85
시가총액:
$308.74M
수익:
$564.17M
순이익/손실:
$37.03M
주가수익비율:
21.92
EPS:
0.1095
순현금흐름:
$-24.46M
1주 성능:
-9.43%
1개월 성능:
-39.70%
6개월 성능:
-47.60%
1년 성능:
-52.66%
1일 변동 폭
$2.305
$2.435
1주일 범위
$2.305
$2.7119
52주 변동 폭
$2.305
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
명칭
Organogenesis Holdings Inc
전화
781-575-0775
주소
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
2.40 | 308.74M | 564.17M | 37.03M | -24.46M | 0.1095 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-28 | 개시 | Lake Street | Buy |
| 2024-02-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-10 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-08-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-08-26 | 재개 | Credit Suisse | Outperform |
| 2019-05-02 | 개시 | Credit Suisse | Outperform |
| 2019-04-17 | 개시 | Oppenheimer | Outperform |
| 2019-04-11 | 개시 | SunTrust | Buy |
모두보기
Organogenesis Holdings Inc 주식(ORGO)의 최신 뉴스
Trading Recap: How does Organogenesis Holdings Inc correlate with Nasdaq2026 Analyst Calls & Growth Focused Stock Pick Reports - baoquankhu1.vn
Amniotic Membrane Market Is Booming Rapidly and Thriving by 2033 - openPR.com
Organogenesis $ORGO Shares Acquired by First Light Asset Management LLC - MarketBeat
Insider Buying: Organogenesis (NASDAQ:ORGO) Director Buys $13,400.00 in Stock - MarketBeat
Insider Buying: Michael Driscoll Acquires Shares of Organogenesis Holdings Inc (ORGO) - GuruFocus
Organogenesis director Leibowitz buys $13k in ORGO stock - Investing.com
Organogenesis (NASDAQ:ORGO) Director Michael Joseph Driscoll Purchases 10,000 Shares of Stock - MarketBeat
Organogenesis (ORGO) director adds 10,000 shares in open-market purchase - Stock Titan
Organogenesis (NASDAQ:ORGO) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Organogenesis (NASDAQ:ORGO) Upgraded by Wall Street Zen to “Buy” Rating - Defense World
Earnings Beat: Will Organogenesis Holdings Inc. stock gain from lower inflationWeekly Trade Report & Verified Technical Signals - Naître et grandir
Organogenesis (ORGO) VP uses 700 shares to cover tax withholding - Stock Titan
Organogenesis (ORGO) VP amends Form 4 for equity grant and tax withholding - Stock Titan
ORGO (Organogenesis) CEO amends Form 4 for stock grant and tax share disposal - Stock Titan
[Form 4/A] Organogenesis Holdings Inc. Amended Insider Trading Activity - Stock Titan
Organogenesis (ORGO) VP updates Form 4 for award vesting and tax shares - Stock Titan
Organogenesis (NASDAQ: ORGO) officer amends Form 4 for award and tax-withheld shares - Stock Titan
BTIG Research Cuts Organogenesis (NASDAQ:ORGO) Price Target to $8.00 - Defense World
Organogenesis Earnings Call: Record Highs Meet Policy Shock - TipRanks
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2025 Earnings Call Transcript - Insider Monkey
ORGO PE Ratio & Valuation, Is ORGO Overvalued - Intellectia AI
Wall Street Zen Downgrades Organogenesis (NASDAQ:ORGO) to Hold - MarketBeat
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Unveiling a Potential 116% Upside in Healthcare Innovation - DirectorsTalk Interviews
Organogenesis Holdings (ORGO) Margin-Driven Profitability Shift Tests Revenue Concern Narratives - simplywall.st
Organogenesis (ORGO) CAO files Form 3 detailing stock and RSUs - Stock Titan
Organogenesis Holdings Reports Q4 2025 Results: Full Earnings Call Transcript - Benzinga
Organogenesis (NASDAQ:ORGO) Price Target Cut to $8.00 by Analysts at BTIG Research - MarketBeat
Organogenesis Q4 Earnings Call Highlights - Yahoo Finance
Organogenesis Holdings Inc (ORGO) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid ... - Investing.com Canada
Organogenesis (ORGO) Q4 2025 Earnings Transcript - AOL.com
Earnings call transcript: Organogenesis Q4 2025 beats expectations but faces market challenges - Investing.com Canada
ORGO: Record Q4 revenue, but 2026 guidance signals a sharp decline before expected recovery - TradingView
Organogenesis: Q4 Earnings Snapshot - Barchart.com
Organogenesis Holdings Inc. (ORGO) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
ORGO: Record 2025 results, but 2026 revenue expected to decline due to CMS changes before recovery - TradingView
Wound-care firm Organogenesis hits record sales, warns 2026 drop up to 38% - Stock Titan
A Preview Of Organogenesis Hldgs's Earnings - Benzinga
Published on: 2026-02-25 08:32:12 - baoquankhu1.vn
Organogenesis Holdings Inc expected to post earnings of 21 cents a shareEarnings Preview - TradingView
Organogenesis Names Patrick McGuire Chief Accounting Officer - The Globe and Mail
Organogenesis (Nasdaq: ORGO) appoints Patrick McGuire as CAO - Stock Titan
Organogenesis Holdings Inc. Announces Executive Changes, Effective February 18, 2026 - marketscreener.com
Organogenesis (NASDAQ: ORGO) legal chief granted options, RSUs and settles taxes - Stock Titan
Executive equity awards at Organogenesis (ORGO) include RSUs, options and tax withholding - Stock Titan
Organogenesis Holdings (NASDAQ: ORGO) COO gets new stock and option awards - Stock Titan
Equity grant gives Organogenesis (ORGO) director 48,828 RSUs vesting 2027 - Stock Titan
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
48,828 RSUs granted to Organogenesis (ORGO) director Arthur Leibowitz - Stock Titan
What’s the fair value of Organogenesis Holdings Inc. stockJuly 2025 Price Swings & Verified Momentum Stock Ideas - mfd.ru
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring a 113% Potential Upside in Healthcare Innovation - DirectorsTalk Interviews
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading CompaniesGilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More - Yahoo Finance
Organogenesis Holdings Inc (ORGO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Organogenesis Holdings Inc 주식 (ORGO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Driscoll Michael Joseph | Director |
Mar 09 '26 |
Buy |
2.67 |
10,000 |
26,688 |
225,707 |
| NUSSDORF GLENN H | Director |
Dec 16 '25 |
Sale |
5.14 |
200,000 |
1,027,060 |
2,565,591 |
2.02%
0.77%
자본화:
|
볼륨(24시간):